Summary
GS70 Chart
GSK's Exdensur Gets FDA Nod for Severe Asthma Treatment
GSK secures FDA approval for Exdensur, the first twice-yearly biologic for treating severe asthma with an eosinophilic phenotype.
US FDA approves GSK's twice-yearly asthma drug
The U.S. Food and Drug Administration has approved GSK's add-on drug to treat asthma and a chronic inflammatory sinus condition, the drugmaker said on Tuesday, paving the way for a less frequently dosed treatment option for patients to enter the market.
UK approves GSK's twice-yearly asthma drug
UK's health regulator on Monday approved GSK's twice-yearly drug for use as an add-on treatment for asthma in patients aged 12 and older, as well as for a chronic inflammatory sinus condition in adults.
GSK plc Sponsored ADR (GS70) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has GSK plc Sponsored ADR ever had a stock split?
GSK plc Sponsored ADR Profile
| Pharmaceuticals Industry | Healthcare Sector | Emma Natasha Walmsley CEO | XFRA Exchange | US37733W2044 ISIN |
| GB Country | 68,629 Employees | 14 Nov 2025 Last Dividend | 22 Jul 2022 Last Split | - IPO Date |
Overview
GSK plc, previously known as GlaxoSmithKline plc until its name change in May 2022, stands as a formidable entity in the pharmaceutical sector with a rich history dating back to 1715. With its global headquarters in Brentford, the United Kingdom, GSK focuses on the research, development, and manufacturing of pharmaceuticals, including vaccines and specialty medicines aimed at preventing and treating a myriad of diseases. This multinational corporation has a broad operational footprint spanning the United Kingdom, the United States, and other international markets. GSK is structured into two main operational segments: Commercial Operations and Total R&D (Research & Development), indicating a robust commitment to innovation in healthcare. Additionally, GSK plc actively engages in strategic collaborations, such as those with CureVac for mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for the advancement of oligonucleotide platform technologies.
Products and Services
GSK's portfolio encompasses a wide range of vaccines and medications designed to combat various diseases, underpinned by the company's significant investments in research and development:
- Vaccines: GSK’s vaccine division offers preventive solutions for shingles, meningitis, respiratory syncytial virus (RSV), flu, polio, and influenza. The company also addresses global healthcare needs by developing vaccines for pandemics, illustrating its commitment to public health and safety.
- HIV Medicines: GSK plc is a key player in the fight against HIV/AIDS, providing innovative medicines that are essential in the management of this chronic condition, thereby improving the quality of life for those affected.
- Oncology: The company’s oncology portfolio consists of treatments for various cancers, underscoring GSK's role in advancing cancer care through research and development of new, potentially life-saving therapies.
- Respiratory/Immunology: GSK offers inhaled medications for asthma and chronic obstructive pulmonary disease (COPD), in addition to medicines for other respiratory and immunological conditions. These products reflect the company’s dedication to enhancing respiratory health and immune system management.
- Antibiotics: Recognizing the importance of combating infectious diseases, GSK also manufactures antibiotics to treat a range of infections, contributing to the global fight against antibiotic resistance and infectious threats.
- Collaborative Agreements: Beyond its in-house product line, GSK engages in strategic collaborations to develop next-generation vaccines and therapies, such as mRNA-based influenza vaccines in partnership with CureVac, and advancements in oligonucleotide platform technologies with Wave Life Sciences and Elsie Biotechnologies, Inc. These partnerships are vital to GSK’s strategy of leveraging external expertise and technology to enhance its R&D pipeline.
